Log in to your Inderes Free account to see all free content on this page.

Gabather

0.678

SEK

+35.6 %

GABA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

1 following

+35.6%

+4.63%

-7.12%

-54.58%

-50.07%

-69.39%

-82.87%

-83.36%

-95.74%

www.gabather.com

Gabather is a pharmaceutical company. Today, there is a business focus on developing drug candidates for the treatment of nerve diseases. Particular focus is on the stimulation of gamma-aminobutyric acid, which is the main inhibitory neurotransmitter in the brain. The drug candidates are today patented on a global level. Gabather was established in 2014 and is headquartered in Malmö.

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Target price

-

Recommendation

-

Updated

-

First North Stockholm

GABA

Daily low / high price

0.678 / 0.698 SEK

Market cap

16.08M SEK

Turnover

413.11 SEK

Volume

603

Financial calendar

Interim report

28.11.2024

Annual report

27.02.2025

Major Owners
Source: Millistream Market Data AB

Owner	Capital	Votes
Avanza Pension	12.6 %	12.6 %
Nordnet Pension	2.2 %	2.2 %

Premium

This content is for our Premium customers only.

Login in to make your own estimates and see other investors estimates.

ShowingAll content types

Regulatory press release4/10/2024, 11:00 AM

Gabather AB: Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002

Press release3/18/2024, 7:30 AM

Gabather AB: Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders

Press release3/7/2024, 8:02 AM

Gabather AB: Gabather reports initial positive results from the EEG/fMRI target engagement study

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release12/22/2023, 2:03 PM

Gabather AB receives initial EEG data analysis from the GT-002 target engagement study

Regulatory press release12/14/2023, 8:16 AM

Gabather AB initiates discussions with specialist doctors and researchers at Karolinska Institutet for the design of a study in individuals at risk of developing frontotemporal dementia (FTD)

Regulatory press release12/11/2023, 12:23 PM

Gabather AB broadens the scope of EEG data analysis generated during the target engagement study by partnering with MINDIG

Regulatory press release10/12/2023, 12:00 PM

Gabather AB: Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy Volunteers

Regulatory press release4/13/2023, 6:45 AM

Gabather AB: Gabather, Receives Notice of Approval from the Japanese Patent Office (JPO) for its National Phase Application No. 2020-554957

Regulatory press release6/7/2022, 8:57 AM

Gabather AB, receives Notice of Allowance from the U.S. Patent Office for its U.S. patent application publication No. US 2021/0087193 A1

Press release6/2/2022, 8:00 AM

Gabather AB: BioStock: Gabather's lead candidate moves forward in the clinic

Regulatory press release5/17/2022, 1:36 PM

Gabather AB: Gabather receives approval to start the EEG/fMRI target engagement study with the drug candidate GT-002

Regulatory press release3/22/2022, 8:00 AM

Gabather AB invited by the Alzheimer's Drug Discovery Foundation, USA to submit a grant application to expand the studies with GT-002 in preclinical models of Alzheimer's disease

Regulatory press release9/14/2021, 6:37 AM

Gabather AB: BioStock: Gabather poised to complete phase I with GT-002

Regulatory press release5/10/2021, 8:19 AM

Gabather AB: BioStock: Covid unmasks need for better mental health medication